Hyperthyroidism: Multimedia

References

1. Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid. 2008;18:333-46. [Medline].

2. Bahn R. The EUGOGO consensus statement on the management of Graves' orbitopathy: equally applicable to North American clinicians and patients. Thyroid. 2008;18:281-2. [Medline].

3. Yoshimura Noh J, Miyazaki N, et al. Evaluation of a new rapid and fully automated electrochemiluminescence immunoassay for thyrotropin receptor autoantibodies. Thyroid. 2008;18:1157-64. [Medline].

4. US Preventative Services Task Force. Screening for thyroid disease: recommendation statement. Ann Intern Med. Jan 20 2004;140(2):125-7. [Medline].

5. FDA MedWatch Safety Alerts for Human Medical Products. Propylthiouracil (PTU). US Food and Drug Administration. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm164162.htm. Accessed June 3, 2009.

6. Allannic H, Fauchet R, Orgiazzi J, et al. Antithyroid drugs and Graves disease: a prospective randomized evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab. 1990;70:675-679. [Medline].

7. Bazakis AM, Kunzler C. Altered mental status due to metabolic or endocrine disorders. Emerg Med Clin North Am. Aug 2005;23(3):901-8, x-xi. [Medline].

8. Buckingham BA, Costin G, Roe TF, et al. Hyperthyroidism in children. A reevaluation of treatment. Am J Dis Child. Feb 1981;135(2):112-7. [Medline].

9. Collen RJ, Landaw EM, Kaplan SA, Lippe BM. Remission rates of children and adolescents with thyrotoxicosis treated with antithyroid drugs. Pediatrics. Mar 1980;65(3):550-6. [Medline].

10. Cooper DS. Antithyroid drugs. N Engl J Med. Nov 22 1984;311(21):1353-62. [Medline].

11. Dallas J, Foley T. Hyperthyroidism. In: Pediatric Endocrinology. 3rd ed. 1996:401-415.

12. Daneman D, Howard NJ. Neonatal thyrotoxicosis: intellectual impairment and craniosynostosis in later years. J Pediatr. Aug 1980;97(2):257-9. [Medline].

13. Gorton C, Sadeghi-Nejad A, Senior B. Remission in children with hyperthyroidism treated with propylthiouracil. Long-term results. Am J Dis Child. Oct 1987;141(10):1084-6. [Medline].

14. Hayek A, Chapman EM, Crawford JD. Long-term results of treatment of thyrotoxicosis in children and adolescents with radioactive iodine. N Engl J Med. Oct 29 1970;283(18):949-53. [Medline].

15. Hershman JM. Does thyroxine therapy prevent recurrence of Graves hyperthyroidism?. J Clin Endocrinol Metab. May 1995;80(5):1479-80. [Medline].

16. Karpman BA, Rapoport B, Filetti S, Fisher DA. Treatment of neonatal hyperthyroidism due to Graves disease with sodium ipodate. J Clin Endocrinol Metab. 1987;64:119-123. [Medline].

17. Kubo T, Shimizu J, Furujo M, et al. An infant case of Graves disease with ophthalmopathy. Endocr J. Oct 2005;52(5):647-50. [Medline].

18. LaFranchi S, Mandel SH. Graves disease in the neonatal period and childhood. 1996;1000-1008.

19. Lippe BM, Landaw EM, Kaplan SA. Hyperthyroidism in children treated with long-term medical therapy: twenty-five percent remission every two years. J Clin Endocrinol Metab. Jun 1987;64(6):1241-5. [Medline].

20. Malabu UH, Alfadda A, Sulimani RA, et al. Graves' disease in Saudi Arabia: a ten-year hospital study. J Pak Med Assoc. 2008;58:302-304. [Medline].

21. McIver B, Rae P, Beckett G, et al. Lack of effect of thyroxine in patients with Graves hyperthyroidism who are treated with an antithyroid drug. N Engl J Med. 1996;334:220-224. [Medline].

22. Nabhan ZM, Kreher NC, Eugster EA. Hashitoxicosis in children: clinical features and natural history. J Pediatr. Apr 2005;146(4):533-6. [Medline].

23. Pagliara AS, Caplan RH, Gundersen CB, et al. Peripheral resistance to thyroid hormone in a family: heterogeneity of clinical presentation. J Pediatr. Aug 1983;103(2):228-32. [Medline].

24. Read CH, Tansey MJ, Menda Y. A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' patients. J Clin Endocrinol Metab. Sep 2004;89(9):4229-33. [Medline]. [Full Text].

25. Rojdmark S, Calissendorff J, Danielsson O, Brismar K. Hunger-satiety signals in patients with Graves thyrotoxicosis before, during, and after long-term pharmacological treatment. Endocrine. Jun 2005;27(1):55-61. [Medline].

26. Ruiz M, Rajatanavin R, Young RA, et al. Familial dysalbuminemic hyperthyroxinemia: a syndrome that can be confused with thyrotoxicosis. N Engl J Med. Mar 18 1982;306(11):635-9. [Medline].

27. Safa AM, Schumacher OP, Rodriguez-Antunez A. Long-term follow-up results in children and adolescents treated with radioactive iodine (131I) for hyperthyroidism. N Engl J Med. Jan 23 1975;292(4):167-71. [Medline].

28. Shiroozu A, Okamura K, Ikenoue H, et al. Treatment of hyperthyroidism with a small single daily dose of methimazole. J Clin Endocrinol Metab. Jul 1986;63(1):125-8. [Medline].

29. Sills IN. Hyperthyroidism. Pediatr Rev. Nov 1994;15(11):417-21. [Medline].

30. Slyper AH, Wyatt D, Boudreau C. Effective methimazole dose for childhood Graves disease and use of free triiodothyronine combined with concurrent thyroid-stimulating hormone level to identify mild hyperthyroidism and delayed pituitary recovery. J Pediatr Endocrinol Metab. 2005;18:597-602. [Medline].

31. Tamai H, Hayaki I, Kawai K, et al. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves disease patients. J Clin Endocrinol Metab. 1995;80:1481-1484. [Medline].

32. Vaidya VA, Bongiovanni AM, Parks JS, et al. Twenty-two years experience in the medical management of juvenile thyrotoxicosis. Pediatrics. Nov 1974;54(5):565-70. [Medline].

33. Zimmerman D, Gan-Gaisano M. Hyperthyroidism in children and adolescents. Pediatr Clin North Am. Dec 1990;37(6):1273-95. [Medline].

34. Zimmermann MB, Ito Y, Hess SY, et al. High thyroid volume in children with excess dietary iodine intakes. Am J Clin Nutr. Apr 2005;81(4):840-4. [Medline]. [Full Text].

Further Reading

Keywords

hyperthyroidism, thyrotoxicosis, Graves disease, Graves' disease, thyroid disease, thyroid gland, thyroid hormone, thyroid-stimulating hormone, TSH, thyrotropin-releasing hormone, TRH, triiodothyronine, T3, thyroxine, T4, diabetes mellitus, Addison disease, systemic lupus erythematosus, rheumatoid arthritis, myasthenia gravis, vitiligo, immune thrombocytopenic purpura, pernicious anemia, treatment, diagnosis, craniosynostosis, developmental delay, hypercalcemia, McCune-Albright syndrome, precocious puberty, attention deficit hyperactivity, disorder, insomnia, heat intolerance, diarrhea, menstrual irregularities, goiter, tachycardia, exophthalmos, toxic adenoma, toxic nodular goiter, subacute thyroiditis, chronic lymphocytic thyroiditis, pituitary adenoma, exogenous thyroid hormone, polyostotic fibrous dysplasia, café-au-lait spots, Jod-Basedow phenomenon

Contributor Information and Disclosures

Author

Robert J Ferry Jr, MD, Chief, Division of Pediatric Endocrinology and Metabolism, Le Bonheur Children's Medical Center, University of Tennessee Health Science Center at Memphis, and St Jude Children's Research Hospital; Field Surgeon (Medical Corps), 162nd Area Support Medical Company, Army National Guard
Robert J Ferry Jr, MD is a member of the following medical societies: American Academy of Pediatrics, American Diabetes Association, American Medical Association, Endocrine Society, Lawson-Wilkins Pediatric Endocrine Society, Society for Pediatric Research, and Texas Pediatric Society
Disclosure: Nutropin Speakers Bureau Honoraria Speaking and teaching; Genotropin Speakers Bureau Honoraria Speaking and teaching; Eli Lilly & Co. Grant/research funds Independent contractor; MacroGenics, Inc. Grant/research funds Independent contractor; Ipsen, S.A. (formerly Tercica, Inc.) Grant/research funds Independent contractor

Coauthor(s)

Jonathan G Gold, MD, Assistant Professor, Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University
Jonathan G Gold, MD is a member of the following medical societies: Ambulatory Pediatric Association, American Academy of Pediatrics, and Sigma Xi
Disclosure: Nothing to disclose.

Medical Editor

Thomas A Wilson, MD, Professor of Clinical Pediatrics, Department of Pediatrics; Director of Pediatric Endocrinology, Division of Pediatric Endocrinology, Department of Pediatrics, State University of New York at Stony Brook
Thomas A Wilson, MD is a member of the following medical societies: Endocrine Society, Lawson-Wilkins Pediatric Endocrine Society, and Phi Beta Kappa
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London), Professor and Chair, First Department of Pediatrics, Athens University Medical School, Aghia Sophia Children's Hospital, Greece
George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London) is a member of the following medical societies: American Academy of Pediatrics, American College of Endocrinology, American College of Physicians, American Pediatric Society, American Society for Clinical Investigation, Association of American Physicians, Endocrine Society, Lawson-Wilkins Pediatric Endocrine Society, and Society for Pediatric Research
Disclosure: Nothing to disclose.

CME Editor

Merrily P M Poth, MD, Professor, Department of Pediatrics and Neuroscience, Uniformed Services University of the Health Sciences
Merrily P M Poth, MD is a member of the following medical societies: American Academy of Pediatrics, Endocrine Society, and Lawson-Wilkins Pediatric Endocrine Society
Disclosure: Nothing to disclose.

Chief Editor

Stephen Kemp, MD, PhD, Professor, Department of Pediatrics, Section of Pediatric Endocrinology, University of Arkansas and Arkansas Children's Hospital
Stephen Kemp, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Association of Clinical Endocrinologists, American Pediatric Society, Endocrine Society, Phi Beta Kappa, Southern Medical Association, and Southern Society for Pediatric Research
Disclosure: Genentech, Inc. Honoraria Speaking and teaching; Pfizer, Inc. Honoraria Consulting